Trade Mark Journal No.2026/036 4 September 2026
WO0000001933378 (5)
Office of origin: European Union Intellectual Property Office (EUIPO)
Date of International Registration:27 May 2026
Date of designation in the UK:
27 May 2026
The mark contains the colours light blue, navy and purple.
International priority date claimed: 22 May 2026
(European Union Intellectual Property Office (EUIPO))
(019369013)
- Class 5
- Pharmaceutical preparations for the prevention and treatment of alzheimer's disease; pharmaceutical preparations for the prevention and treatment of depression; pharmaceutical preparations for the prevention and treatment of psychological disorders; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of osteoporosis; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of sexual dysfunction; pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; pharmaceutical preparations for the prevention and treatment of aids-related disorders; pharmaceutical preparations that support, encourage and promote bone strength; pharmaceutical preparations that support, encourage and promote bone health; pharmaceutical preparations used in the treatment of bone disorders and bone diseases; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations, namely, contraceptive preparations; pharmaceutical preparations, namely, fertility enhancement preparations; pharmaceutical preparations, namely, hormone replacement therapy preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical agents affecting the central nervous system; pharmaceutical agents affecting circulatory systems; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting urogenital organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for the treatment of neurological disorders.
Teva Pharmaceuticals International GmbH
Representative: FRKelly, Waterways House, Grand Canal Quay,, Dublin , D02 PD39, IRELAND